CADL Candel Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why CADL matters now
Candel Therapeutics, Inc. (CADL) is a US stock in Healthcare. The latest InvestLog snapshot shows $12.86 with -2.06% on the session and $942.3M in market capitalization; recent performance reads 1-month +8.49% and YTD +47.08%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.9M, and EPS of $-0.14. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.7%.
The latest indexable market news headline is "Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes Loggia Nicoletta filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.75
P/S
0.00
EV/EBITDA
-5.23
DCF Value
$2.20
FCF Yield
-10.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.4%
ROA
-27.0%
ROIC
-28.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.9M | $-0.14 |
| Q4 2025 | $0.00 | $-29.5M | $-0.54 |
| FY 2025 | $0.00 | $-38.2M | $-0.72 |
| Q3 2025 | $0.00 | $-11.3M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.48
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.